Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Population-based pharmacokinetic and pharmacodynamic dosing model of epirubicin, cyclophosphamide and docetaxel for breast cancer
2009-011113-25Phase 4Terminated
- Sponsor
- Per Honoré
- Start
- May 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of epirubicin, cyclophosphamide and docetaxel in breast cancer, sponsored by Per Honoré. Primary endpoints: Population-based pharmacokinetic model and PK-PD and adverse event relationships. Started May 2009; status: terminated.
02
Drugs
epirubicincyclophosphamidedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-011113-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011113-25.